Skip to main content

Your basket

Your basket is empty. Continue shopping to add products to your basket.

Search our catalogue

Call Centre

Request Quote

Please enter the quantity of products you want a quote for

Please enter the date you need these products byPlease enter a date in the format DD/MM/YYYY

View Content

Please complete the form below to receive the requested content from Astrea Bioseparations. We will use the data you provide to send you relevant updates, special offers, and product-related information. See our Privacy Notice for details on how we use personal data.

If you have an account please log in to gain access to content. You can apply for an account here

Please enter a First Name

Please enter a valid First Name, the maximum length is 50 characters.

Please enter a Last Name

Please enter a valid Last Name, the maximum length is 50 characters.

Please enter a Company Name

Please enter a valid Company, the maximum length is 100 characters

Please enter a valid Email AddressPlease enter a valid Email AddressThe Email Address entered is already registered, please sign in with the Email Address or enter a different one

Please select a valid Telephone Number, the maximum length is 30 characters

Please enter a valid Telephone Number consisting only of the following characters and spaces ( ) + 0 1 2 3 4 5 6 7 8 9

Please select a State / Province / Territory

Please select a valid State / Province / Territory, the maximum length is 150 characters

Please select a Country

Data entered into form will be stored in your session (not in a cookie) to avoid having to re-enter in future form submissions.

MARC HUMMERSONE

 

MARC HUMMERSONE

SENIOR DIRECTOR OF R & D

 

Marc Hummersone has over 20 years of project and managerial experience in both big and small technology companies, including industry leaders AstraZeneca, General Electric Healthcare & Cytiva. He has a broad experience base across a wide range of technologies including the development of novel chromatographic media for the purification of complex biological feed streams as well as drug discovery and development. He was a key contributor to the development of the Fibro chromatography family of products which resulted in the acquisition of Puridify, by GE Healthcare in 2017. Additionally, he was a key part of the management team who validated the concept of synthetic lethality and who identified and developed Lynparza, which is an approved drug for the treatment of BRCA-mutated advanced ovarian cancer which resulted in the acquisition of KuDOS Pharmaceuticals in 2005, by AstraZeneca. Marc has held positions including Company Director, Chief Scientific Officer and Department Director. He gained a PhD and Post-Doctoral experience in chemistry which was focused on the total synthesis of complex natural products at University College, London.


CONNECT ON LinkedIn

Call Centre Product Compare